FDA updates in urology: March 2025

Welcome to Urology Times’® monthly FDA update! This month, key developments include the initiation of a pivotal trial in stress urinary incontinence (SUI), an expanded indication for radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC), and the approval of a new treatment regimen in muscle-invasive bladder cancer (MIBC).